RT Journal Article
T1 Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
A1 Perkovic, Vlado
A1 Jardine, Meg J
A1 Neal, Bruce
A1 Bompoint, Severine
A1 Heerspink, Hiddo J L
A1 Charytan, David M
A1 Edwards, Robert
A1 Agarwal, Rajiv
A1 Bakris, George
A1 Bull, Scott
A1 Cannon, Christopher P
A1 Capuano, George
A1 Chu, Pei-Ling
A1 de Zeeuw, Dick
A1 Greene, Tom
A1 Levin, Adeera
A1 Pollock, Carol
A1 Wheeler, David C
A1 Yavin, Yshai
A1 Zhang, Hong
A1 Zinman, Bernard
A1 Meininger, Gary
A1 Brenner, Barry M
A1 Mahaffey, Kenneth W
A1 CREDENCE Trial Investigators, 
AB Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium-glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to 300 to 5000) and were treated with renin-angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of  The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P = 0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years. (Funded by Janssen Research and Development; CREDENCE ClinicalTrials.gov number, NCT02065791.).
YR 2019
FD 2019-04-14
LK https://hdl.handle.net/10668/26680
UL https://hdl.handle.net/10668/26680
LA en
DS RISalud
RD Apr 13, 2025